Product information and disease descriptionProduct descriptionProduct information
Special populations
7 evidence topics · 9 sources
CYP2D6 poor metabolizers
“Individuals with no functional CYP2D6 (i.e., poor metabolizers) had longer LSD half-lives and approximately 75% higher parent drug and main metabolite 2-oxo-3-hydroxy LSD area-under-the-curve blood plasma concentrations compared with carriers of functional CYP2D6.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Non-functional CYP2D6 metabolizers also exhibited greater alterations of mind and longer subjective effect durations in response to LSD compared with functional CYP2D6 metabolizers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CYP2D6 is associated with several phenotypes, ranging from poor metabolizers (PMs; 5–10% in Caucasians) to ultra-rapid metabolizers (UMs; 3–5% in Caucasians), with different underlying genotypes” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Geno- or phenotyping may be useful in patients who undergo LSD-assisted therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on the present findings, CYP2D6 PMs may benefit from approximately 50% lower doses than those that are used in functional CYP2D6 individuals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote